Published On: Fri, Jun 19th, 2020

Merck completes acquisition of Austrian vaccine developer Themis Bioscience

Tagged with: | | | | |

Pharma giant Merck has wrapped up its previously announced acquisition of Austrian vaccine developer Themis Bioscience.

The Austrian company is focused on developing and immune-modulation for infectious diseases and cancer.

Merck announced the deal last month in a move to gain access to Themis Bioscience’s vaccine candidate. Read more about Merck acquisition of Themis Bioscience here.

The transaction was cleared by the US Federal Trade Commission and prior to that Merck had secured merger control clearance from the Austrian Federal Competition Authority.

Themis is now a fully-owned subsidiary of Merck.

The pharma giant said that it will initially focus on speeding up the development of Themis Bioscience’s vector-based candidate, which is presently in pre-clinical development. Clinical studies of the candidate are targeted to begin later this year.

Related posts